BOSTON, Nov. 10, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced that David
Mauney, M.D., CBO and interim COO, will present at the Stifel 2017 Healthcare Conference in New York on Tuesday, November 14, 2017
at 11:00 a.m. ET.
To access a live audio webcast of the presentation, please visit the Investor Relations section at
www.ziopharm.com. The webcast will be archived for 90 days.
About ZIOPHARM Oncology, Inc.:
ZIOPHARM Oncology is a Boston, Massachusetts-based biotechnology company employing innovative gene expression,
control and cell technologies to deliver safe, effective and scalable cell- and viral-based therapies for the treatment of cancer
and graft-versus-host-disease. The Company's immuno-oncology programs, in collaboration with Intrexon Corporation (NYSE:XON) and
the MD Anderson Cancer Center, include chimeric antigen receptor T cell (CAR-T) and other adoptive cell-based approaches that use
non-viral gene transfer methods for broad scalability. The Company is advancing programs in multiple stages of development together
with Intrexon Corporation's RheoSwitch Therapeutic System® (RTS®) technology, a switch to turn on and off, and precisely modulate,
gene expression in order to improve therapeutic index. The Company's pipeline includes a number of cell-based therapeutics in both
clinical and preclinical testing which are focused on hematologic and solid tumor malignancies.
Contact:
David Pitts
Argot Partners
212-600-1902
david@argotpartners.com
